Home > Boards > US Listed > Medical - Drugs > AIkido Pharma Inc (AIKI)

Alexander Poltorak was appointed as a director in

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
investora2z Member Profile
 
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/5/2020 4:44:18 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 9/23/2020 5:05:30 PM
AIkido Pharma Announces Update On Its Use Of Artificial Intelligence PR Newswire (US) - 9/18/2020 10:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/14/2020 4:58:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/11/2020 4:18:15 PM
AIkido Pharma Inc. Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16... PR Newswire (US) - 9/11/2020 10:00:00 AM
AIkido Pharma Announces Peer-Reviewed Publication of Positive Results from Study of Antiviral Compounds Licensed from Univers... PR Newswire (US) - 9/11/2020 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/31/2020 4:28:00 PM
AIkido Pharma Sponsors Survival Study of University of Kentucky Anticancer Drug G4-1 in Exchange for Exclusive Option to Lice... PR Newswire (US) - 8/18/2020 9:00:00 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 8/17/2020 4:31:28 PM
AIkido Pharma Inc. to Present at The LD 500 Virtual Conference PR Newswire (US) - 8/14/2020 9:00:00 AM
Option for Treatment for Coronavirus Extended PR Newswire (US) - 8/11/2020 10:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 4:57:13 PM
AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements PR Newswire (US) - 8/3/2020 10:00:00 AM
AIkido Pharma Inc. Announces Key Progress in Computational Approaches to Identify Virus Treatments, Including Coronavirus PR Newswire (US) - 7/9/2020 1:31:00 PM
AIkido Pharma Inc. Provides Update to Machine Learning Pancreatic Cancer Research PR Newswire (US) - 6/26/2020 10:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2020 9:55:07 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/19/2020 6:00:46 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 6/12/2020 3:21:30 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 6/8/2020 3:04:29 PM
AIkido Pharma Announces Publication of Results from Sponsored Research at Wake Forest University PR Newswire (US) - 5/28/2020 10:00:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/19/2020 5:36:14 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/19/2020 5:34:49 PM
AIkido Pharma Inc. Announces Distribution of Hoth Dividend PR Newswire (US) - 5/19/2020 10:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2020 4:07:29 PM
investora2z   Sunday, 11/03/13 10:11:16 AM
Re: None
Post # of 8101 
Alexander Poltorak was appointed as a director in the company. Poltorak was the Chairman and CEO of General Patent, an intellectual property management firm focusing on IP strategy and valuation, patent licensing, enforcement and brokerage. The CEO of Spherix stated that Poltorak's extensive experience in the patent monetization industry will provide valuable governance leadership to Spherix. An article on seekingalpha also mentions that 'Poltorak is a pioneer in this industry and has looked at more patents than almost anyone over the past couple of decades. He has spent his working life focused squarely on the intellectual property business, and his decision to join Spherix is another strong indication of the quality of the company's portfolio.' The author has also mentioned that though it is difficult to value the patents owned by Spherix, the deal with Rockstar and the leadership of Hayes were good enough reasons to invest in this high-risk, high-reward bet. The transaction with Rockstar involved granting ownership of certain patents to Spherix in exchange for shares of Spherix (instead of cash) as well as a share in future profits from these patents. So 'it appears to be a situation where Rockstar is turning the patents over to Spherix who is highly motivated to extract value from them.' Hayes has a successful track record of monetization of patents in many other organizations. The fact that Hayes has joined Spherix indicates that he sees value in these patents. Considering the experience he has in the industry, his opinion or decision needs to be given due weightage. The author mentions that the low float makes the stock extremely volatile. He also mentions that Spherix is just beginning to explore ways to extract value from its patents, and it is difficult to estimate the future cash flows.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences